SLC5A2 and type 2 diabetes mellitus: In a three-year follow-up study, Ishibashi et al. [162] aimed to demonstrate whether SGLT2-i offered protection against diabetic neuropathy and nephropathy in patients with T2DM by reducing the variability in glycemia and extra glycemic factors or their average.